Review
Pharmacology & Pharmacy
Jillian Marie Walker, Padraic O'Malley, Mei He
Summary: Muscle invasive bladder cancer (MIBC) is a subtype of bladder cancer with a high risk of metastasis and death. Current diagnostic methods include urologic evaluation, CT scan, urinalysis, and cystoscopy. However, these invasive procedures carry risks and potential health concerns. Exosomes, as a novel source of biomarkers, show promise in addressing some of the limitations of urine cytology. This review provides an overview of MIBC, current urine cytology methods, the role of exosomes, and their potential as a diagnostic tool.
Article
Biochemistry & Molecular Biology
Sara Monteiro-Reis, Vera Miranda-Goncalves, Catarina Guimaraes-Teixeira, Claudia Martins-Lima, Joao Lobo, Diana Montezuma, Paula C. Dias, Helene Neyret-Kahn, Isabelle Bernard-Pierrot, Rui Henrique, Carmen Jeronimo
Summary: In this study, we found that the VIM promoter is epigenetically regulated in normal and neoplastic urothelium, leading to a switch in VIM expression associated with EMT and the acquisition of invasive and metastatic properties. These findings might contribute to the development of novel therapeutic strategies for bladder cancer based on epigenetics.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2023)
Article
Oncology
Ji-Qing Chen, Lucas A. Salas, John K. Wiencke, Devin C. Koestler, Annette M. Molinaro, Angeline S. Andrew, John D. Seigne, Margaret R. Karagas, Karl T. Kelsey, Brock C. Christensen
Summary: This study used DNA methylation profiles and cell type analysis to identify that increasing CD4T and CD8T cell proportions were associated with a decreased hazard of tumor recurrence or death in NMIBC patients, while increasing monocyte proportion and mdNLR were associated with an increased hazard. Additionally, 2528 CpGs associated with tumor recurrence or death were identified through epigenome-wide association study.
CLINICAL EPIGENETICS
(2022)
Article
Oncology
Shiv Verma, Eswar Shankar, Spencer Lin, Vaibhav Singh, E. Ricky Chan, Shufen Cao, Pingfu Fu, Gregory T. MacLennan, Lee E. Ponsky, Sanjay Gupta
Summary: This study identified a 3-gene signature panel with prognostic value in bladder cancer, including CDKN2A, CDC20, CTSV, FOXM1, MAGEA6, KRT23, and S100A9. These genes were confirmed to have strong prognostic values in bladder cancer and were validated through qRT-PCR in various human bladder cancer cells representing stage-specific disease progression. Additionally, ULCAN, human protein atlas, and The Cancer Genome Atlas datasets were used to confirm the predictive value of these genes in bladder cancer progression.
Review
Oncology
Giandomenico Roviello, Martina Catalano, Raffaella Santi, Matteo Santoni, Ilaria Camilla Galli, Andrea Amorosi, Wojciech Polom, Ugo De Giorgi, Gabriella Nesi
Summary: Urothelial carcinoma of the bladder is a common cancer with various treatment approaches, and immunotherapy and targeted therapy have shown promising results in extending survival.
FRONTIERS IN ONCOLOGY
(2022)
Article
Engineering, Biomedical
Guangzhi Li, Tao Tao, Dashi Deng, Shaohua Zhang, Yu Chao, Yizhi Dai, Yuqing Li, Ran Tao, Simin Yuan, Zhuang Liu, Song Wu
Summary: Polyethylene glycol (PEG) and glutaraldehyde co-modified fluorinated chitosan (PGFCS) can enhance the transepithelial penetration of chemotherapeutic agents and create a tumor-targeted adhesive interface in bladder cancer treatment by improving the bladder epithelial barrier.
Article
Medicine, General & Internal
Hai Huang, Ao Liu, Yiming Liang, Yaqun Xin, Jiacheng Liu, Yining Hao, Da Huang, Lu Chen, Wei Li, Guangliang Jiang, Yuhua Huang, Yaoting Xu, Jie Zhang, Tonghui Ma, Danfeng Xu, Yi Gao
Summary: This study evaluated the performance of OncoUrine in diagnosing non-muscle invasive bladder cancer (NMIBC) patients. The results showed that OncoUrine has a high sensitivity and specificity in bladder cancer diagnosis and recurrence monitoring, reducing the frequency of unnecessary cystoscopy and correlating with recurrence-free survival in NMIBC patients.
Article
Oncology
Aleksander Slusarczyk, Piotr Zapala, Lukasz Zapala, Tomasz Borkowski, Piotr Radziszewski
Summary: This study aimed to report the real-world cancer-specific survival (CSS) of non-muscle-invasive bladder cancer (NMIBC) and develop a prognostic nomogram based on identified risk factors. The results showed that long-term cancer-specific mortality (CSM) is high in NMIBC, especially for T1HG patients. T1LG and TaHG tumors should also be considered high-risk due to their relatively high CSM. T category, grading, and age are the most important predictors of CSS in NMIBC.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Urology & Nephrology
G. Cancel-Tassin, M. Roupret, U. Pinar, C. Gaffory, F. Vanie, V. Ondet, E. Comperat, Olivier Cussenot
Summary: The Xpert Bladder Cancer (BC) Monitor showed superior performance compared to cytology in the follow-up of patients with non-muscle invasive bladder cancer (NMIBC). It can effectively exclude the presence of aggressive tumors with a very high negative predictive value (99.7%).
WORLD JOURNAL OF UROLOGY
(2021)
Article
Oncology
Anastasia C. Hepburn, Nicola Lazzarini, Rajan Veeratterapillay, Laura Wilson, Jaume Bacardit, Rakesh Heer
Summary: Chemotherapy prior to bladder removal benefits muscle-invasive bladder cancer patients, but identifying responders remains a challenge. A novel gene set and CNGB1 show promise as biomarkers, but require further validation.
Review
Biotechnology & Applied Microbiology
Carmine Valenza, Gabriele Antonarelli, Federica Giugliano, Gaetano Aurilio, Elena Verri, Alberto Briganti, Giuseppe Curigliano, Andrea Necchi
Summary: The article provides an overview of clinical trials investigating innovative immunological and target agents in patients with BCG unresponsive and BCG naive NMIBC. Promising treatment options such as pembrolizumab, atezolizumab, oportuzumab monatox, nadofaragene firadenovec, and N-803 are emerging.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2022)
Review
Biochemistry & Molecular Biology
Vincenzo Fiorentino, Cristina Pizzimenti, Mariausilia Franchina, Esther Diana Rossi, Pietro Tralongo, Angela Carlino, Luigi Maria Larocca, Maurizio Martini, Guido Fadda, Francesco Pierconti
Summary: The management of NMIBC requires monitoring and evaluation methods such as urinary cytology, cystoscopy, and radiological assessment of the upper urinary tract. Urine cytology and methylation analysis are commonly used methods with high sensitivity for detecting high-grade bladder carcinoma and carcinoma in situ. The combined use of urine cytology and methylation analysis can diagnose high-grade bladder carcinoma and predict clinical and histological recurrences in doubtful cases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Weizhuo Wang, Xi Zhang, Silin Jiang, Peng Xu, Kang Chen, Kai Li, Fei Wang, Xiang Le, Ke Zhang
Summary: This study aimed to construct a prognostic model based on differential gene expression between muscular and non-muscular invasive bladder cancer (BCa), and to investigate the prognosis of BCa patients. BCa patient data from GEO and TCGA databases were analyzed, and single-cell sequencing and microarray data were used to validate the differential gene expression. The prognostic model showed accuracy and validity, and S100A9 may be a better prognostic marker and therapeutic target for BCa.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Camille Mazza, Vincent Gaydou, Jean-Christophe Eymard, Philippe Birembaut, Valerie Untereiner, Jean-Francois Cote, Isabelle Brocheriou, David Coeffic, Philippe Villena, Stephane Larre, Vincent Vuiblet, Olivier Piot
Summary: Assessing the tumor response to chemotherapy is crucial for improving patient care. In this study, we used infrared spectroscopy to analyze tissue samples from muscle-invasive bladder cancer and developed a classification model to predict the response to chemotherapy. This study highlights the potential of infrared imaging for personalized treatment.
Review
Urology & Nephrology
J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, Eva M. Comperat, Nigel C. Cowan, Georgios Gakis, Virginia Hernandez, Estefania Linares Espinos, Anja Lorch, Yann Neuzillet, Mathieu Rouanne, George N. Thalmann, Erik Veskimae, Maria J. Ribal, Antoine G. van der Heijden
Summary: This article presents the updated European Association of Urology guidelines for muscle-invasive and metastatic bladder cancer, providing practical evidence-based recommendations and consensus statements on clinical management. The guidelines cover a broad scope and incorporate the latest research findings and results from consensus meetings.
